What was the market valuation of the UK gene therapy market in 2024?

The market valuation was $306.0 Million in 2024. Read More

What is the projected market valuation for the UK gene therapy market by 2035?

The projected market valuation for 2035 is $2082.0 Million. Read More

What is the expected CAGR for the UK gene therapy market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 19.04%. Read More

Which companies are considered key players in the UK gene therapy market?

Key players include Novartis, Gilead Sciences, Sangamo Therapeutics, Bluebird Bio, Spark Therapeutics, CRISPR Therapeutics, Bristol-Myers Squibb, Roche, and AstraZeneca. Read More

What are the two main types of vectors used in gene therapy, and what were their valuations in 2024?

In 2024, Viral Vector was valued at $200.0 Million, while Non-Viral Vector was valued at $106.0 Million. Read More

What types of gene therapies are included in the market, and what were their valuations in 2024?

In 2024, Antigen therapies were valued at $30.6 Million, Cytokine and Tumor Suppressor therapies at $61.2 Million each, and others varied from $0.0 to $208.2 Million. Read More

What applications are driving the UK gene therapy market, and what were their valuations in 2024?

In 2024, Rare Diseases had a valuation of $91.8 Million, while Oncological Disorders were valued at $61.2 Million. Read More

What delivery methods are utilized in gene therapy, and what were their valuations in 2024?

In 2024, In Vivo Gene Therapy was valued at $122.4 Million, and Ex Vivo Gene Therapy at $183.6 Million. Read More

How does the UK gene therapy market compare to other regions?

While specific regional comparisons are not provided, the UK market is poised for substantial growth, indicated by its projected valuation increase. Read More

What factors contribute to the growth of the UK gene therapy market?

Factors include advancements in technology, increasing prevalence of genetic disorders, and the presence of leading companies driving innovation. Read More

UK Gene Therapy Market

ID: MRFR/Pharma/51497-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

UK Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Applications (Research, Clinical, Commercial) and By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Vector Type (USD Million)
  1. 4.1.1 Viral Vector
  2. 4.1.2 Non-Viral Vector
2. 4.2 Life Sciences, BY Gene Type (USD Million)
  1. 4.2.1 Antigen
  2. 4.2.2 Cytokine
  3. 4.2.3 Tumor Suppressor
  4. 4.2.4 Suicide
  5. 4.2.5 Deficiency
  6. 4.2.6 Growth Factors
  7. 4.2.7 Receptors
  8. 4.2.8 Others
3. 4.3 Life Sciences, BY Application (USD Million)
  1. 4.3.1 Oncological Disorders
  2. 4.3.2 Rare Diseases
  3. 4.3.3 Cardiovascular Diseases
  4. 4.3.4 Neurological Disorders
  5. 4.3.5 Infectious Diseases
  6. 4.3.6 Others
4. 4.4 Life Sciences, BY Delivery Method (USD Million)
  1. 4.4.1 In Vivo Gene Therapy
  2. 4.4.2 Ex Vivo Gene Therapy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sangamo Therapeutics (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bluebird Bio (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Spark Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 CRISPR Therapeutics (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY VECTOR TYPE
3. 6.3 UK MARKET ANALYSIS BY GENE TYPE
4. 6.4 UK MARKET ANALYSIS BY APPLICATION
5. 6.5 UK MARKET ANALYSIS BY DELIVERY METHOD
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY VECTOR TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY VECTOR TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY GENE TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY GENE TYPE, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY DELIVERY METHOD, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY VECTOR TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY GENE TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Life Sciences Market Segmentation

Life Sciences By Vector Type (USD Million, 2025-2035)

Viral Vector
Non-Viral Vector

Life Sciences By Gene Type (USD Million, 2025-2035)

Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth Factors
Receptors
Others

Life Sciences By Application (USD Million, 2025-2035)

Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Others

Life Sciences By Delivery Method (USD Million, 2025-2035)

In Vivo Gene Therapy
Ex Vivo Gene Therapy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”